Abstract: Methylthioadenosine phosphorylase (MTAP) deletion is a common genetic alteration in various cancers, including approximately 15% of non-small cell lung cancers (NSCLC). This deletion leads to the accumulation of methylthioadenosine (MTA), which partially inhibits protein arginine methyltransferase 5 (PRMT5), creating a unique synthetic lethal vulnerability. AMG 193 is a novel, orally bioavailable, MTA-cooperative PRMT5 inhibitor designed to selectively target MTAP-deleted tumors while sparing healthy tissues. Preclinical and early clinical data demonstrate that AMG 193 effectively inhibits tumor growth and reduces symmetric dimethylarginine (SDMA) levels with a favorable safety profile, notably lacking the severe hematologic toxicities associated with earlier non-selective PRMT5 inhibitors. This review summarizes the pharmacological activity, molecular mechanism, structure-activity relationship, limitations, and future perspectives of AMG 193, with a specific focus on its application and combinatorial potential in NSCLC.
1. Introduction
Targeted therapies have significantly improved survival outcomes in cancer, yet the continuous pursuit of novel anticancer agents remains critical. A prominent emerging strategy involves exploiting synthetic lethality in tumors harboring specific genetic deletions. The MTAP gene, located on the chromosome 9p21 locus adjacent to the CDKN2A tumor suppressor gene, is homozygously deleted in approximately 10% of all human cancers, including roughly 15% of non-small cell lung cancer (NSCLC) cases [1]. MTAP is an essential enzyme in the methionine and adenine salvage pathways, responsible for metabolizing methylthioadenosine (MTA). Its deletion results in a significant intracellular accumulation of MTA [1].
Early attempts to target the PRMT5 pathway utilized S-adenosyl methionine (SAM)- and substrate-competitive inhibitors. However, these non-selective agents caused severe off-target cytotoxicity, particularly dose-limiting hematologic adverse events like anemia and thrombocytopenia, leading to the termination of several clinical trials [1]. To overcome this narrow therapeutic window, MTA-cooperative PRMT5 inhibitors such as AMG 193 were developed. AMG 193 selectively targets the PRMT5-MTA complex enriched in MTAP-deleted cells, offering a highly specific synthetic lethal approach for NSCLC and other MTAP-deficient solid tumors [1].
2. Pharmacological Activity
In preclinical models, AMG 193 demonstrated robust, dose-dependent tumor growth inhibition across a variety of MTAP-deleted xenograft models, including NSCLC, pancreatic ductal adenocarcinoma (PDAC), and melanoma [1]. Importantly, this efficacy was achieved without marked toxicity, weight loss, or the significant hematologic toxicity typically seen with non-selective PRMT5 inhibitors [1].
Clinically, AMG 193 is being evaluated in a Phase I/Ib trial (NCT05094336) involving patients with advanced MTAP-deleted solid tumors who had received a median of two prior lines of therapy. In the dose-exploration phase, the maximum tolerated dose (MTD) was established at 1,200 mg once daily [1]. Among 74 evaluable patients, the overall response rate (ORR) was 12.2% and the disease control rate (DCR) was 47.3%. Efficacy was more pronounced at active dosage levels (800 and 1,200 mg once daily, and 600 mg twice daily), where the ORR increased to 21.4% and the DCR to 54.8%, with a median duration of response (DOR) of 8.3 months [1]. Objective responses were observed across multiple tumor types, including NSCLC [1].
The safety profile of AMG 193 is highly favorable compared to first-generation inhibitors. While 85% of patients experienced treatment-related adverse events (TRAEs)—most commonly nausea (48.8%), fatigue (31.3%), and vomiting (30%)—Grade ≥3 TRAEs occurred in only 13.8% of patients. Crucially, treatment-related anemia was observed in ≤10% of patients, confirming the improved therapeutic window of this MTA-cooperative approach [1].
3. Molecular Mechanism of Action
The mechanism of action of AMG 193 is rooted in the metabolic consequences of MTAP deficiency. In healthy cells, MTAP metabolizes MTA, maintaining a balance that allows PRMT5 to utilize SAM for the symmetric dimethylation of arginine residues on histones and target proteins involved in RNA splicing, cell cycle progression, and DNA repair [1]. In MTAP-deleted cancer cells, the inability to metabolize MTA causes its intracellular levels to rise by an average of 15-fold. This accumulated MTA outcompetes SAM for binding to PRMT5, forming a PRMT5-MTA complex and partially inhibiting PRMT5 activity [1].
AMG 193 acts as an MTA-cooperative inhibitor by selectively binding to and stabilizing this PRMT5-MTA complex. By doing so, it further suppresses PRMT5 activity exclusively in MTAP-deleted cells, sparing healthy MTAP wild-type cells [1]. Pharmacodynamic modeling in patients treated with AMG 193 showed a significant dose-response relationship, with near-complete elimination of symmetric dimethylarginine (SDMA) observed at active dosage levels [1]. Preclinically, AMG 193 inhibited SDMA by 86% to 93% in MTAP-deleted tumors versus only 26% to 76% in MTAP wild-type tumors. This profound PRMT5 inhibition disrupts RNA splicing (primarily by inducing intron retention), triggers DNA damage, and alters cell cycle pathways, ultimately driving synthetic lethality in the tumor cells [1].
4. Structure-Activity Relationship (SAR)
AMG 193 was discovered through high-throughput screening for small molecules that bind selectively to PRMT5 in the presence of MTA, followed by iterative structure-based drug design to optimize potency and selectivity [1]. X-ray crystallography of the PRMT5-binding structure reveals that AMG 193 occupies the substrate binding site of the PRMT5-MTA complex. The compound forms tight van der Waals interactions with the MTA molecule while simultaneously interfering with the interaction between PRMT5 and SAM [1]. This specific structural engagement contributes to a long dissociation half-life and confers high binding selectivity for the PRMT5-MTA complex over the PRMT5-SAM complex, which is the structural basis for its tumor-selective pharmacological profile [1].
5. Current Limitations
Despite promising early data, the clinical application of AMG 193 faces several limitations. First, the kinetics of tumor regression appear delayed compared to traditional targeted therapies (e.g., tyrosine kinase inhibitors). The median time to response for AMG 193 was 3.6 months at 800 mg once daily and 1.8 months at 1,200 mg once daily, suggesting that deepening tumor regression occurs over a longer period, necessitating extended patient follow-up to fully ascertain clinical benefit [1].
Second, there is a critical need for predictive biomarkers beyond MTAP deletion itself to identify which patients will derive the most benefit. While MTAP deletion is necessary, response rates indicate it is not solely sufficient for efficacy [1]. Furthermore, accurately identifying MTAP deficiency in the clinic remains complex. While next-generation sequencing (NGS) can detect MTAP genomic deletions, some tumors exhibit MTAP protein loss via epigenetic silencing without genomic deletion, complicating patient selection and highlighting the potential need for complementary immunohistochemistry (IHC) testing [1].
6. Future Perspectives
The future development of AMG 193 in NSCLC and other solid tumors is heavily focused on combinatorial strategies to enhance depth and durability of response:
Combination with Targeted Therapies: AMG 193 is being investigated in combination with the KRAS G12C mutant-selective inhibitor sotorasib in NSCLC and PDAC models, with a Phase I trial (NCT06333951) currently underway. Early data suggest that co-occurring KRAS mutations do not confer resistance to MTA-cooperative PRMT5 inhibition, making this a highly rational combination [1].
Combination with Chemotherapy: Because MTAP is responsible for salvaging adenine, MTAP-deleted tumors are highly susceptible to adenine depletion. Pemetrexed, an antifolate commonly used in NSCLC, targets de novo purine synthesis. MTAP deficiency is a known predictive biomarker for pemetrexed efficacy in lung cancer. Consequently, the combination of AMG 193 with pemetrexed (and other chemotherapies like carboplatin and paclitaxel) is being actively explored in clinical trials (NCT06333951, NCT06360354) [1].
Combination with MAT2A Inhibitors: Dual inhibition of the PRMT5 pathway using AMG 193 alongside MAT2A inhibitors (which deprive PRMT5 of its methyl donor, SAM) has shown synergistic effects in preclinical NSCLC models, leading to deep and sustained regressions [1].
Biomarker Discovery: Future research will focus on identifying biomarkers of sensitivity, such as the expression ratio of PRMT5 co-factors (CLNS1A and RIOK1) or the loss of splicing regulators like CAAP1 and AKAP17A, which may sensitize NSCLC cells to PRMT5 inhibition [1]. These advancements will be crucial in optimizing patient selection and maximizing the therapeutic potential of AMG 193.
